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Indications and pitfalls of immunohistochemistry in head and 
neck cancer
Abstract
Décio de Natale Caly1, Acklei Viana2, Abrão Rapoport3, Rogério Aparecido Dedivitis4, 
Otávio Alberto Curioni5, Cláudio Roberto Cernea6, Lenine Garcia Brandão7
Immunohistochemistry (IHC) has been employed in the differential diagnosis of tumors.
Objective: To assess the use of IHC in cases of head and neck tumor.
Method: This is a retrospective study of the cases included in the Cancer Registry of the institution.
Results: IHC was used in 76 (11%) of 704 pathology tests. Most cases were carcinomas (85.80%), 
and 83.66% of them were squamous cell carcinomas. All tests were done with diagnostic purposes. 
The most frequently used antibodies were 34BE12 (37.18%), AE1/AE3 (35.9%), 35BH11 (28.21%), 
CD45 (25.64%), CD20 (24.36%), CD30 (24.36%), CK7 (23.08%) and CD3 (23.08%).
Conclusions: IHC was used in 10.67% of the head and neck tumor cases submitted to pathology 
testing, mostly for carcinoma (5.26%). In the determination of squamous cell carcinoma, IHC 
accounted for 18.42% of all tumors.
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INTRODUCTION
Macro and microscopic alterations lie in the basis 
of pathology diagnostics, and microscopic morphology 
plays a fundamental role in the interpretation of histo-
genesis, classification, and prognostic assessment of tu-
mors. However, in the 1970s more elaborate techniques 
gained significant ground in aiding in the diagnosis of 
cases in which the assessment produced from the use 
of the usual histochemical stains was not conclusive. 
Immunohistochemistry (IHC) protocols were developed 
in this setting, using antibodies tagged with chromogens 
to identify specific markers. In these protocols, antigen-
antibody reactions using non-fluorescent chromogens are 
analyzed in an optical microscope. IHC is performed in 
paraffin-embedded specimens sliced on a microtome and 
submitted to treatments for antigen retrieval, processed 
with immunoperoxidase and development reagents1,2. 
The ease of handling paraffin-embedded specimens has 
granted significant popularity to IHC in pathology labs.
Despite the relevant contributions offered by IHC, 
the assessment of the specimens and the determination 
of which panel to use is made only after careful analysis 
by the pathologist through traditional pathology testing 
protocols.
The main indications for IHC are: definition of 
histogenesis; differential diagnosis between reactive and 
neoplastic states; etiologic diagnosis of infectious diseases; 
determination of prognostic factors; determination of target 
therapy sites; location of primary tumors in malignant dis-
ease; determination of specific products (such as hormones 
and proteins); and cancer subtyping.
In the definition of histogenesis, assessment is 
carried out to determine the tissue and/or cell origin of 
a specific cell population. In the case of neoplasms, IHC 
provides substantial help in defining whether the tumor 
derives from epithelial, mesenchymal, hematopoietic, or 
nervous tissue.
The criteria to define whether a tumor is benign 
or malignant are still strongly founded in morphology. 
Macroscopically, features such as infiltrative growth pat-
tern, borders of the tumor, absence of a tumor capsule, 
growth rate, necrosis, and hemorrhage are considered. 
Microscopically, cell count and anaplasia (cell and nucleus 
pleomorphism, atypical mitosis, and nuclear-cytoplasmic 
ratio) are analyzed.
It is important that these ideas be considered, as 
when IHC is used to determine histogenesis, the tests yield 
positive results for the same markers based on tissue origin 
and not on whether the tumor is benign or malignant, i.e., 
normal malpighian (squamous) epithelium will be marked 
the same way as squamous cell carcinoma.
Histological classification is based on the criteria 
defined by Broders, in which cell differentiation and 
keratinization of tumor cells are categorized into four 
grades of final differentiation3. Squamous cell carcinoma 
(SCC) may present the following variants, according to the 
classification of the World Health Organization: verrucous, 
basaloid, papillary, spindle-cell, acantholytic, adenosqua-
mous, and cuniculatum4.
However, neoplasms other than SCC may involve 
the head and neck area, including undifferentiated carci-
nomas, metastasis, neuroendocrine carcinomas, sarcomas, 
lymphomas, etc.
In this setting IHC is required to produce diagnosis 
and subtype tumors. Despite the routine use of IHC and 
its ample availability for clinical and surgical personnel, it 
is worthwhile discussing its use and precise indications in 
diagnostics, prognostics, the possible impacts it may have 
upon therapy, and the technique’s limitations. Thus, this 
paper aimed to assess the use of IHC in cases of head 
and neck cancer.
METHOD
This retrospective study looked into the pathology 
test results of the Cancer Registry of the institution dated 
from April 2009 to February 2012, and included cases of 
the hospital’s Head and Neck Service.
Enrollment criteria included: subjects diagnosed 
and treated at the institution with cases entered into the 
Hospital Cancer Registry; pathology tests filed in electronic 
format in the Hospital Cancer Registry. Exclusion criteria: 
lack of IHC testing support; thyroid tumors; basal-cell 
carcinoma of the skin and cutaneous attachments; and 
odontogenic tumors.
The study included cases processed by IHC pro-
tocols, considering the incidence rates of various tumor 
types - carcinomas, sarcomas, and lymphomas - and 
utilized panels.
Descriptive analysis was performed based on ab-
solute and relative frequencies.
RESULTS
A grand total of 677 pathology test results were 
selected; IHC was not performed in 605 (89.4%) cases; 
seventy-two (10.6%) cases had IHC test results.
Considering the split of tumor types, carcinomas ac-
counted for 94.69% of the cases, followed by lymphomas 
(3.84%). IHC panels for diagnostic purposes were used 
in 10.64% of the cases, 5.47% of which were epithelial 
tumors. IHC was done in all cases of lymphoma and 
sarcoma (Table 1). In terms of histological subtypes, SCC 
accounted for most cases (87%). The other subtypes are 
listed on Table 2.
In the 72 cases submitted to immunohistochemistry 
testing, SCC (19.44%) and diffuse large cell lymphomas tied 
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for first (19,44%), followed by node metastasis (12.50%), 
Hodgkin’s lymphoma (9.72%), and undifferentiated carci-
noma (8.33%) (Table 3).
When incidence rates within specific tumor groups 
(carcinoma, lymphoma, sarcoma) were compared for diag-
nosed subtypes for which IHC was done, the highest rates 
in the carcinoma group went to SCC, with 37.84%; in the 
lymphoma group, diffuse large B-cell lymphoma ranked 
first, with 53.85%; and in the sarcoma group, pleomorphic 
sarcoma was the most commonly observed tumor type, 
with 28.57% (Tables 4, 5, and 6).
The 76 immunohistochemistry tests were done with 
diagnostic purposes. Considering the chosen IHC panels 
and antibodies, 34BE12 (37.18%), AE1/AE3 (35.90%), 
35BH11 (28.21%), CD45 (25.64%), CD20 (24.36%), CD30 
(24.36%), CK7 (23.08%) and CD3 (23.08%) were the most 
frequently used (Table 7).
DISCUSSION
Immunohistochemistry has significantly improved 
the outlook for pathology tests. The possibility of obtaining 
Table 1. Distribution of diagnoses.
No IHC IHC Total
Cases Percent Cases Percent Cases Percent
Carcinoma 604 89.22% 37 5.47% 641 94.68%
Lymphoma 0 0.00% 26 3.84% 26 3.84%
Sarcoma 0 0.00% 7 1.03% 7 1.03%
Melanoma 1 0.15% 2 0.30% 3 0.44%
Total 605 89.36% 72 10.64% 677 100.00%
Table 2. Distribution of histological tumor subtypes.
No IHC IHC Total
Cases Percent Cases Percent Cases Percent
Squamous cell carcinoma 575 84.93% 14 2.07% 589 87.00%
Undifferentiated carcinoma 16 2.36% 6 0.89% 22 3.25%
Node metastasis by adenocarcinoma 8 1.18% 9 1.33% 17 2.51%
Mucoepidermoid carcinoma 1 0.15% 1 0.15% 2 0.30%
Adenoid cystic carcinoma 1 0.15% 1 0.15% 2 0.30%
Parotid adenocarcinoma 1 0.15% 2 0.30% 3 0.44%
Nasopharyngeal carcinoma 0 0.00% 1 0.15% 1 0.15%
Small-cell carcinoma 1 0.15% 1 0.15% 2 0.30%
Palate adenocarcinoma 0 0.00% 1 0.15% 1 0.15%
Neuroendocrine carcinoma 1 0.15% 1 0.15% 2 0.30%
Pleomorphic sarcoma 0 0.00% 2 0.30% 2 0.30%
Undifferentiated sarcoma 0 0.00% 1 0.15% 1 0.15%
Fibromyxoid sarcoma 0 0.00% 1 0.15% 1 0.15%
Chondrosarcoma 0 0.00% 1 0.15% 1 0.15%
Leiomyosarcoma 0 0.00% 1 0.15% 1 0.15%
Angiosarcoma 0 0.00% 1 0.15% 1 0.15%
Hodgkin’s lymphoma 0 0.00% 7 1.03% 7 1.03%
Diffuse large B-cell non-Hodgkin’s lymphoma 0 0.00% 14 2.07% 14 2.07%
Mantle cell lymphoma 0 0.00% 1 0.15% 1 0.15%
Plasmablastic lymphoma 0 0.00% 2 0.30% 2 0.30%
Anaplastic large cell lymphoma 0 0.00% 1 0.15% 1 0.15%
Follicular lymphoma 0 0.00% 1 0.15% 1 0.15%
Melanoma 0 0.15% 2 0.30% 3 0.44%
Total 605 89.36% 72 10.64% 677 100.00%
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Table 3. Distribution of diagnoses obtained from immunohistochemistry testing.
Cases Percent
Squamous cell carcinoma 14 19.44%
Undifferentiated carcinoma 6 8.33%
Node metastasis by adenocarcinoma 9 12.50%
Mucoepidermoid carcinoma 1 1.39%
Adenoid cystic carcinoma 1 1.39%
Parotid adenocarcinoma 2 2.78%
Nasopharyngeal carcinoma 1 1.39%
Small-cell carcinoma 1 1.39%
Palate adenocarcinoma 1 1.39%
Neuroendocrine carcinoma 1 1.39%
Pleomorphic sarcoma 2 2.78%
Undifferentiated sarcoma 1 1.39%
Fibromyxoid sarcoma 1 1.39%
Chondrosarcoma 1 1.39%
Leiomyosarcoma 1 1.39%
Angiosarcoma 1 1.39%
Hodgkin’s lymphoma 7 9.72%
Diffuse large B-cell non-Hodgkin’s lymphoma 14 19.44%
Mantle cell lymphoma 1 1.39%
Plasmablastic lymphoma 2 2.78%
Anaplastic large cell lymphoma 1 1.39%
Follicular lymphoma 1 1.39%
Melanoma 2 2.78%
Total 72 100.00%
Table 4. Distribution of carcinomas tested with immunohistochemistry based on subtypes.
Cases Percent
Squamous cell carcinoma 14 37.84%
Undifferentiated carcinoma 6 16.22%
Node metastasis by adenocarcinoma 9 24.32%
Mucoepidermoid carcinoma 1 2.70%
Adenoid cystic carcinoma 1 2.70%
Parotid adenocarcinoma 2 5.41%
Nasopharyngeal carcinoma 1 2.70%
Small-cell carcinoma 1 2.70%
Palate adenocarcinoma 1 2.70%
Neuroendocrine carcinoma 1 2.70%
Total 37 100.00%
clarification on once doubtful and hard-to-diagnose tumors 
turned this technique into a powerful addition to the roster 
of routine test protocols.
Epithelial tissues can be immunolabeled by cyto-
keratins, proteins present in the cytoskeleton of epithelial 
cells. There are more than 25 types of cytokeratin divided 
into low and high molecular weight subtypes. Specific 
tissue types are labeled by specific cytokeratins. Squamous 
epithelium is labeled by high molecular weight cytokera-
tins such as CK4, CK5, CK6, CK13, CK14, CK17 or by a 
cocktail of these cytokeratins called 34βE12. Glandular epi-
thelium is preferentially labeled by low molecular weight 
cytokeratins (CK8, CK18, CK 19) or by a low molecular 
weight cocktail called 35β11.
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In diagnostic terms, IHC in SCC has limited 
effectiveness in subtypes that escape more traditional 
forms of disease. Poorly differentiated carcinomas in 
which histogenesis is needed for the differential diagnosis 
against other tumors such as sarcoma, undifferentiated, 
small-cell and neuroendocrine tumors, also challenge 
the performance of IHC protocols. SCC is labeled by 
the pan-cytokeratin stain (AE1/AE3) and high molecular 
weight cytokeratin complex 34βE12; keratinizing SCC 
of the nasal cavity and paranasal sinuses, basaloid SCC, 
and spindle-cell SCC may require additional markers. 
Even when looking into or confirming the diagnosis of 
SCC, it is important to resort to other markers to perform 
proper differential diagnosis against other tumor types 
(mesenchymal, hematopoietic, adenocarcinomas).
Even though IHC has limited indication for 
head and neck SCC, recent studies have assessed its 
prognostic relevance. Molecular pathways are known to 
participate in carcinogenesis. Among the most studied 
are the p53, p16, cyclin D1, and PTEN pathways. The 
association between p53, cyclin, and p16 labeling and 
tumor thickness, metastasis, and response to adjuvant 
therapy has been analyzed. Correlations have been 
drawn, but no consensus has been reached for head and 
neck SCC5-7. The predictive value of therapeutic response 
to radiotherapy has been targeted by some authors, in 
an attempt to correlate the degree of response to the 
degree of PTEN expression by IHC8,9.
Significant attention has been devoted to the use 
of target therapies in managing tumors. The epidermal 
growth factor receptor (EGFR) pathway acts as an 
oncogene by activating cell proliferation and division. 
When this pathway suffers mutations or is activated, 
keratinocytes are stimulated to proliferate and grow. 
The EGFR pathway is mutated in about 30% of the 
cases of head and neck SCC. EGFR expression has been 
correlated to poorer prognosis10. The use of monoclonal 
antibodies to prevent EGFR activation has garnered 
significant interest. The detection of this receptor 
through IHC aids in the choice of therapy and use of 
specific medication11.
Tumor growth and propagation are directly linked 
to the degree of angiogenesis. Vascular endothelium 
growth factor (VEGF), described in the 1980s, is a 
glycoprotein that binds to specific receptors to act on the 
mechanism of angiogenesis. Angiogenesis is essential 
for tumor growth and propagation and correlates with 
poorer prognosis. More recently, IHC has been used in 
the VEGF pathway to assess patient prognosis; drugs 
such as bevacizumab have been used to block the VEGF 
pathway and attain better control over the disease12,13.
IHC has played a significant role in primary tumor 
site identification in metastatic disease. Panels labeling 
SCC, adenocarcinoma, thyroid carcinoma, sarcoma, 
lymphoma, neuroendocrine carcinoma, and melanoma 
can improve diagnostic accuracy and thus provide 
valuable input to the determination of the most effective 
course of therapy.
All in all, IHC is a good ancillary technique. 
In order to optimize its use, clear indication criteria 
are needed. The technique helps approach head and 
neck tumors, mainly in diagnosing sarcomas and 
lymphomas and enabling their adequate classification. 
Its use is limited in cases of carcinomas characterized 
by diagnostic doubt.
In our series, most tumors were categorized as 
SCC (87%), as also reported in the literature14,15, and 
did not pose significant diagnostic difficulties. IHC was 
used in only 10.67% of the cases of carcinoma, when 
further clarification was needed for diagnosis and 
histogenesis. The use of IHC to confirm histogenesis 
and tumor subtype is supported by the literature16,17. The 
number of cases in our series in which IHC protocols 
Table 5. Distribution of sarcomas submitted to immunohisto-
chemistry testing.
Cases Percent
Pleomorphic sarcoma 2 28.57%
Undifferentiated sarcoma 1 14.29%
Fibromyxoid sarcoma 1 14.29%
Chondrosarcoma 1 14.29%
Leiomyosarcoma 1 14.29%
Angiosarcoma 1 14.29%
Total 7 100.00%
Table 6. Distribution of lymphomas submitted to immunohistochemistry testing.
Cases Percent
Hodgkin’s lymphoma 7 26.92%
Diffuse large B-cell non-Hodgkin’s lymphoma 14 53.85%
Mantle cell lymphoma 1 3.85%
Plasmablastic lymphoma 2 7.69%
Anaplastic large cell lymphoma 1 3.85%
Follicular lymphoma 1 3.85%
Total 26 100.00%
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is not a significant number, the relevance of IHC in 
indicating the correct histogenesis of the neoplasm in 
cases of unidentified primary tumor and consequently 
enhancing the effectiveness of adjuvant therapy cannot 
be neglected.
IHC has undisputed value for other tumor types 
(sarcomas and lymphomas). It has been used in the 
determination of histogenesis and tumor subtyping, and 
has consequently had significant impact on the choice 
of therapy.
CONCLUSION
Immunohistochemistry was used in 10.67% of 
the head and neck tumor cases tested with traditional 
pathology protocols. IHC was more frequently used in 
carcinomas, accounting for 5.26% of all cases. In the de-
termination of squamous cell carcinoma, IHC protocols 
were used in 18.42% of the tumors. The diagnosis of 
squamous cell carcinoma is still done largely without the 
use of immunohistochemistry panels. IHC is required to 
confirm the diagnosis in cases of metastatic disease. It is 
also needed in the diagnosis and subtyping of lymphomas 
and subtyping of sarcomas.
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